[{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Erythromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Eastern Virginia Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Eastern Virginia Medical School","highestDevelopmentStatusID":"10","companyTruncated":"Inova Health Care Services \/ Eastern Virginia Medical School"}]

Find Clinical Drug Pipeline Developments & Deals for Erygel

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Inova Health Care Services

                          Country arrow
                          EPSC
                          Not Confirmed

                          Inova Health Care Services

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          February 23, 2024

                          Lead Product(s) : Erythromycin

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : Eastern Virginia Medical School

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Erythromycin acts by inhibition of protein synthesis by binding to the 23S ribosomal RNA molecule in the 50S subunit of ribosomes in susceptible bacterial organisms.

                          Product Name : Erythromycin

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 03, 2023

                          Lead Product(s) : Erythromycin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 20, 2019

                          Lead Product(s) : Erythromycin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Maruho

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 19, 2018

                          Lead Product(s) : Erythromycin

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Maruho

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIO-Studien-gGmbH

                          Country arrow
                          EPSC
                          Not Confirmed

                          AIO-Studien-gGmbH

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 20, 2012

                          Lead Product(s) : Erythromycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Ectycell

                          Country arrow
                          EPSC
                          Not Confirmed

                          Ectycell

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 19, 2011

                          Lead Product(s) : Erythromycin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Pierre and Marie Curie University | INSERM

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank